{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:13:37Z","timestamp":1790108017112,"version":"4.0.1"},"reference-count":40,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T00:00:00Z","timestamp":1545264000000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>The 2013 Diabetes Canada guidelines launched targeted dissemination tools and a simple assessment for vascular protection. We aimed to 1) examine changes associated with the launch of the 2013 guidelines and additional dissemination efforts in the rates of vascular protective medications prescribed in primary care for older patients with diabetes and 2) examine differences in the rates of prescriptions of vascular protective medications by patient and provider characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>The study population included patients (\u226540 years of age) from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with type 2 diabetes and at least one clinic visit from April 2010 to December 2015. An interrupted time series analysis was used to assess the proportion of eligible patients prescribed a statin, ACE inhibitor (ACEI)\/angiotensin receptor blocker (ARB), or antiplatelet prescription in each quarter. Proton pump inhibitor (PPI) prescriptions were the reference control.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A dynamic cohort was used where participants were enrolled each quarter using a prespecified set of conditions (range 25,985\u201370,693 per quarter). There were no significant changes in statin (P = 0.43), ACEI\/ARB (P = 0.42), antiplatelet (P = 0.39), or PPI (P = 0.16) prescriptions at baseline (guideline intervention). After guideline publication, there was a significant change in slope for statin (\u22120.52% per quarter, SE 0.15, P &amp;lt; 0.05), ACEI\/ARB (\u22120.38% per quarter, SE 0.13, P &amp;lt; 0.05), and reference PPI (\u22120.18% per quarter, SE 0.05, P &amp;lt; 0.05) prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>There was a decrease in prescribing trends over time that was not specific to vascular protective medications. More effective knowledge translation strategies are needed to improve vascular protection in diabetes in order for patients to receive the most effective interventions.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc18-0935","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T15:39:17Z","timestamp":1541173157000},"page":"148-156","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":15,"title":["Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010\u20132015"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-1618","authenticated-orcid":false,"given":"Alanna V.","family":"Rigobon","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Kalia","sequence":"additional","affiliation":[{"name":"University of Toronto Practice-Based Research Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennica","family":"Nichols","sequence":"additional","affiliation":[{"name":"Diabetes Canada, Toronto, Ontario, Canada"},{"name":"Interdisciplinary Studies, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Aliarzadeh","sequence":"additional","affiliation":[{"name":"University of Toronto Practice-Based Research Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8957-0285","authenticated-orcid":false,"given":"Michelle","family":"Greiver","sequence":"additional","affiliation":[{"name":"University of Toronto Practice-Based Research Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"North York General Hospital, Toronto, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim","family":"Moineddin","sequence":"additional","affiliation":[{"name":"University of Toronto Practice-Based Research Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sullivan","sequence":"additional","affiliation":[{"name":"University of Toronto Practice-Based Research Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"North York General Hospital, Toronto, Ontario, Canada"},{"name":"Institute for Clinical Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada"},{"name":"Medical School, University of St Andrews, St Andrews, Scotland, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-1046","authenticated-orcid":false,"given":"Catherine","family":"Yu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"key":"2022031300561960000_B1","first-page":"A357","article-title":"Is the rule of halves applicable in Diabetes Type 2? Evidence from Greece","volume":"17","author":"Tsiantou","year":"2014","journal-title":"Value Health"},{"key":"2022031300561960000_B2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"2022031300561960000_B3","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jcjd.2013.01.030","article-title":"Vascular protection in people with diabetes","volume":"37","author":"Stone","year":"2013","journal-title":"Can J Diabetes"},{"key":"2022031300561960000_B4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2022031300561960000_B5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2022031300561960000_B6","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/dmrr.285","article-title":"Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE","volume":"18","author":"Gerstein","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031300561960000_B7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjd.2013.02.055","article-title":"Type 2 diabetes mellitus management in Canada: is it improving","volume":"37","author":"Leiter","year":"2013","journal-title":"Can J Diabetes"},{"key":"2022031300561960000_B8","first-page":"336","volume-title":"Knowledge Translation in Health Care: Moving From Evidence to Practice","author":"Straus","year":"2011"},{"key":"2022031300561960000_B9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diabres.2018.02.041","article-title":"Impact of the Canadian Diabetes Association guideline dissemination strategy on clinician knowledge and behaviour change outcomes","volume":"140","author":"Yu","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031300561960000_B10","doi-asserted-by":"crossref","first-page":"E371","DOI":"10.25011\/cim.v38i6.26200","article-title":"Sex\/gender-based pharmacology and statin utilization amongst elderly patients with diabetes","volume":"38","author":"Farahani","year":"2015","journal-title":"Clin Invest Med"},{"key":"2022031300561960000_B11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/jep.12104","article-title":"Near equality in quality for medication utilization among older adults with diabetes with universal medication insurance in Ontario, Canada","volume":"20","author":"Shah","year":"2014","journal-title":"J Eval Clin Pract"},{"key":"2022031300561960000_B12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/diacare.29.04.06.dc05-1875","article-title":"Antihypertensive medication prescribing in 27,822 elderly Canadians with diabetes over the past decade","volume":"29","author":"McAlister","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031300561960000_B13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2022031300561960000_B14","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1370\/afm.1644","article-title":"Validating the 8 CPCSSN case definitions for chronic disease surveillance in a primary care database of electronic health records","volume":"12","author":"Williamson","year":"2014","journal-title":"Ann Fam Med"},{"key":"2022031300561960000_B15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ije\/dyw248","article-title":"Data Resource Profile: National electronic medical record data from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN)","volume":"46","author":"Garies","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2022031300561960000_B16","volume-title":"Guidelines for ATC Classification and DDD Assignment 2018","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2017"},{"key":"2022031300561960000_B17"},{"key":"2022031300561960000_B18","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.jcjd.2013.01.037","article-title":"Chronic kidney disease in diabetes","volume":"37","author":"McFarlane","year":"2013","journal-title":"Can J Diabetes"},{"key":"2022031300561960000_B19","first-page":"1","article-title":"Data and analysis methodology","volume-title":"Reducing Gaps in Health: A Focus on Socio-Economic Status in Urban Canada","author":"Canadian Institute for Health Information","year":"2008"},{"key":"2022031300561960000_B20"},{"key":"2022031300561960000_B21","volume-title":"Obesity: Preventing and Managing the Global Epidemic","author":"World Health Organization","year":"1998"},{"key":"2022031300561960000_B22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/00273171.2012.715557","article-title":"Modeling time-dependent association in longitudinal data: a lag as moderator approach","volume":"47","author":"Selig","year":"2012","journal-title":"Multivariate Behav Res"},{"key":"2022031300561960000_B23","unstructured":"Canadian Institute for Health Information. National prescription drug utilization information system database plan information document [Internet], 2012. Available from https:\/\/secure.cihi.ca\/free_products\/PlanInformation_1007_e1.pdf. Accessed 25 October 2017"},{"key":"2022031300561960000_B24","first-page":"564","article-title":"Variation in refill protocols and procedures in a family medicine residency network","volume":"44","author":"Guirguis-Blake","year":"2012","journal-title":"Fam Med"},{"key":"2022031300561960000_B25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"2022031300561960000_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"2022031300561960000_B27"},{"key":"2022031300561960000_B28","volume-title":"The Statistical Analysis of Time Series","author":"Anderson","year":"2011"},{"key":"2022031300561960000_B29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1503\/cmaj.131674","article-title":"Engaging physicians and patients in conversations about unnecessary tests and procedures: Choosing Wisely Canada","volume":"186","author":"Levinson","year":"2014","journal-title":"CMAJ"},{"key":"2022031300561960000_B30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0828-282X(10)70393-7","article-title":"Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada","volume":"26","author":"Braga","year":"2010","journal-title":"Can J Cardiol"},{"key":"2022031300561960000_B31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12927\/hcq.2016.24617","article-title":"Increasing access to health administrative data with ICES data & analytic services","volume":"19","author":"Ishiguro","year":"2016","journal-title":"Healthc Q"},{"key":"2022031300561960000_B32","first-page":"137","article-title":"Rural, suburban, and urban differences in factors that impact physician adherence to clinical preventive service guidelines elaine","volume":"150","author":"Khoong","year":"2016","journal-title":"J Rural Health"},{"key":"2022031300561960000_B33","first-page":"e155","article-title":"Association of enrolment in primary care networks with diabetes care and outcomes among First Nations and low-income Albertans","volume":"6","author":"Campbell","year":"2012","journal-title":"Open Med"},{"key":"2022031300561960000_B34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1758-5996-6-53","article-title":"Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes","volume":"6","author":"Liew","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"2022031300561960000_B35","doi-asserted-by":"crossref","first-page":"e007429","DOI":"10.1136\/bmjopen-2014-007429","article-title":"Glycated haemoglobin A1c is associated with low-grade albuminuria in Chinese adults","volume":"5","author":"Huang","year":"2015","journal-title":"BMJ Open"},{"key":"2022031300561960000_B36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/fampra\/cmh409","article-title":"Quality of morbidity coding in general practice computerized medical records: a systematic review","volume":"21","author":"Jordan","year":"2004","journal-title":"Fam Pract"},{"key":"2022031300561960000_B37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijmedinf.2007.03.001","article-title":"An effort to improve electronic health record medication list accuracy between visits: patients\u2019 and physicians\u2019 response","volume":"77","author":"Staroselsky","year":"2008","journal-title":"Int J Med Inform"},{"key":"2022031300561960000_B38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"key":"2022031300561960000_B39","first-page":"E101","article-title":"How do you know which health care effectiveness research you can trust? A guide to study design for the perplexed","volume-title":"Prev Chronic Dis","author":"Soumerai","year":"2015"},{"key":"2022031300561960000_B40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1010024016308","article-title":"The value of interrupted time-series experiments for community intervention research","volume":"1","author":"Biglan","year":"2000","journal-title":"Prev Sci"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/1\/148\/528307\/dc180935.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/1\/148\/528307\/dc180935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:41:57Z","timestamp":1720744917000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/1\/148\/36322\/Impact-of-the-Diabetes-Canada-Guideline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,11,2]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-0935","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}